Tisch MS News

Two studies from the Tisch MS Center were selected by the American Academy of Neurology (AAN) Science Committee to be highlighted as a significant advance based on animal research. Congratulations to first authors Ruth-Anne Langan (Dr. Violaine Harris' group) and Dr. Marwan Alahiri (Dr. Ying Liu's group) for being selected. 

The stem cell research division of the Tisch MS Research Center of New York is pleased to announce the completed enrollment of 20 patients to participate in the phase I clinical trial investigating the safety and efficacy of autologous, mesenchymal stem cell-derived neural progenitors (MSC-NPs) for the treatment of multiple sclerosis. We are no longer recruiting for this study. Interim results of this clinical trial will be presented at upcoming scientific conferences and simultaneously announced on our website.

The American Academy of Neurology (AAN) recently announced that it accepted eight of the Tisch MS Research Center of New York’s research abstracts to be presented at its 2015 Annual Meeting. This year marks the AAN’s 67th Annual Meeting, which will be held April 18th – 25th at the Walter E. Washington Convention Center in Washington, DC. 

Congratulations to Dr. Saud A. Sadiq who has been recognized in Castle Connolly's "America's Top Doctors" 14th ed. and "Top Doctors: New York Metro Area" 18th ed.

Due to the impending storm and weather conditions, the Tisch MS Research Center of New York will be closed on Tuesday, January 27th.

The Tisch MS Research Center will be closed Monday, January 19th in observance of Dr. Martin Luther King, Jr. Day.

Dr. Massimiliano Cristofanilli and Dr. Fozia Mir presented at the 2014 Society for Neuroscience Meeting in Washington D.C. on November 15th. They spoke to an eager audience of over 200 scientists as part of the Demyelinating Disorders Nanosymposium. The annual meeting of the Society for Neuroscience is the world’s largest event focused on scientific discovery related to the brain and nervous system.

On November 6, Neurology Today Online featured Tisch MSRCNY in a review of news coming out of the ACTRIMS/ECTRIMS Annual Meeting in September examining the safety of stem cell therapy in MS treatment. The article discussed two different trials that were found to be safe and well tolerated in multiple sclerosis patients: one using intravenous injection of mesenchymal stem cells and the other Tisch MSRCNY’s protocol using intrathecal injections of mesenchymal stem cells.

Thank you to all who attended the 17th Annual Tisch MS Research Patient Symposium.  In response to your requests, a review of the material presented will be posted on this website and appear in the next issue of our newsletter, Healing MS.

Dr. Violaine Harris and Dr. Saud A. Sadiq co-authored a review entitled “Biomarkers of Therapeutic Response in Multiple Sclerosis: Current Status and this has been accepted for publication in the Journal  Molecular Diagnosis and Therapy.

Pages

Real Time Analytics